<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36864291</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature reviews. Rheumatology</Title><ISOAbbreviation>Nat Rev Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Treatment of lupus nephritis: consensus, evidence and perspectives.</ArticleTitle><Pagination><StartPage>227</StartPage><EndPage>238</EndPage><MedlinePgn>227-238</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41584-023-00925-5</ELocationID><Abstract><AbstractText>Despite the continuing development of immunomodulatory agents and supportive care, the prognosis associated with lupus nephritis (LN) has not improved substantially in the past decade, with end-stage kidney disease still developing in 5-30% of patients within 10 years of LN diagnosis. Moreover, inter-ethnic variation in the tolerance of, clinical response to and level of evidence regarding various therapeutic regimens for LN has led to variation in treatment prioritization in different international recommendations. Modalities that better preserve kidney function and reduce the toxicities of concomitant glucocorticoids are unmet needs in the development of therapeutics for LN. In addition to the conventional recommended therapies for LN, there are newly approved treatments as well as investigational drugs in the pipeline, including the newer generation calcineurin inhibitors and biologic agents. In view of the heterogeneity of LN in terms of clinical presentation and prognosis, the choice of therapies depends on a number of clinical considerations. Molecular profiling, gene-signature fingerprints and urine proteomic panels might enhance the accuracy of patient stratification for treatment personalization in the future.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chi Chiu</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-3696-1228</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Hong Kong, China. ccmok2005@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Y K Onno</ForeName><Initials>YKO</Initials><AffiliationInfo><Affiliation>Center of Expertise for Lupus-, Vasculitis- and Complement-mediated systemic diseases, Department of Internal Medicine, Section of Nephrology, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saxena</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5722-9509</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Nephrology, UT Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0807-7139</Identifier><AffiliationInfo><Affiliation>The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Rev Rheumatol</MedlineTA><NlmUniqueID>101500080</NlmUniqueID><ISSNLinking>1759-4790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36864291</ArticleId><ArticleId IdType="doi">10.1038/s41584-023-00925-5</ArticleId><ArticleId IdType="pii">10.1038/s41584-023-00925-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mok, C. C. Towards new avenues in the management of lupus glomerulonephritis. Nat. Rev. Rheumatol. 12, 221&#x2013;234 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26729459</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2015.174</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C., Kwok, R. C. L. &amp; Yip, P. S. F. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 65, 2154&#x2013;2160 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23754671</ArticleId><ArticleId IdType="doi">10.1002/art.38006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandane-Rathnayake, R. et al. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. Lupus 28, 1669&#x2013;1677 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31718467</ArticleId><ArticleId IdType="doi">10.1177/0961203319887799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharawala, S. et al. Health-related quality of life, fatigue and health utilities in lupus nephritis: a systematic literature review. Lupus https://doi.org/10.1177/09612033221100910 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221100910</ArticleId><ArticleId IdType="pubmed">35607279</ArticleId><ArticleId IdType="pmc">9277333</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly, M. et al. Disease-specific quality of life in patients with lupus nephritis. Lupus 27, 257&#x2013;264 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28728507</ArticleId><ArticleId IdType="doi">10.1177/0961203317717082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. &amp; Tang, S. S. K. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am. J. Med. 117, 791&#x2013;795 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15541328</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2004.04.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, M. J. &amp; Jawad, A. S. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology 56, i67&#x2013;i77 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27940583</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh, S. V., Almaani, S., Brodsky, S. &amp; Rovin, B. H. Update on lupus nephritis: core curriculum 2020. Am. J. Kidney Dis. 76, 265&#x2013;281 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32220510</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, Y., O&#x2019;Neill, S., Li, M., Tsai, I.-C. &amp; Yang, Y.-W. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific Region. Arthritis Care Res. 74, 187&#x2013;198 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24431</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes, R. W. et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res. 64, 159&#x2013;168 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexton, D. J. et al. ESRD from lupus nephritis in the United States, 1995&#x2013;2010. Clin. J. Am. Soc. Nephrol. 10, 251&#x2013;259 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25534208</ArticleId><ArticleId IdType="doi">10.2215/CJN.02350314</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Puerta, J. A. et al. Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res. 67, 1453&#x2013;1462 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nee, R. et al. Survival disparity of African American versus Non-African American patients with ESRD due to SLE. Am. J. Kidney Dis. 66, 630&#x2013;637 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26002293</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2015.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto, T. &amp; Niewold, T. B. Genetics of human lupus nephritis. Clin. Immunol. 185, 32&#x2013;39 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27693588</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2016.09.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman, B. I. et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 66, 390&#x2013;396 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24504811</ArticleId><ArticleId IdType="pmc">4002759</ArticleId><ArticleId IdType="doi">10.1002/art.38220</ArticleId></ArticleIdList></Reference><Reference><Citation>Portalatin, G. M., Gebreselassie, S. K. &amp; Bobart, S. A. Lupus nephritis &#x2014; an update on disparities affecting African Americans. J. Natl Med. Assoc. 114, S34&#x2013;S42 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35595581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan, J., Thompson, N. J., Dunlop-Thomas, C., Lim, S. S. &amp; Drenkard, C. Relationships among organ damage, social support, and depression in African American women with systemic lupus erythematosus. Lupus 28, 253&#x2013;260 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30482093</ArticleId><ArticleId IdType="doi">10.1177/0961203318815573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, K. et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology 47, 690&#x2013;697 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18375972</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/ken050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoi, A. Asian lupus in a multi-ethnic society: what can be learnt? Int. J. Rheum. Dis. 18, 113&#x2013;116 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25884456</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.12497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Almaraz, E. et al. Something new about prognostic factors for lupus nephritis? A systematic review. Lupus 30, 2256&#x2013;2267 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34907831</ArticleId><ArticleId IdType="doi">10.1177/09612033211061475</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni, G. et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann. Rheum. Dis. 77, 1318&#x2013;1325 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29730634</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-212732</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge, A. et al. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol. 71, 403&#x2013;410 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30225916</ArticleId><ArticleId IdType="pmc">6393198</ArticleId><ArticleId IdType="doi">10.1002/art.40729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou, M. G., Dasgupta, A. &amp; Ward, M. M. Risk of end-stage renal disease in patients with lupus nephritis, 1971&#x2013;2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 68, 1432&#x2013;1441 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26815601</ArticleId><ArticleId IdType="pmc">5071782</ArticleId><ArticleId IdType="doi">10.1002/art.39594</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders, H.-J. et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrol. Dial. Transpl. https://doi.org/10.1093/ndt/gfab351 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab351</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis, A. et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713&#x2013;723 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32220834</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatol. 3, e517&#x2013;e531 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00009-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases. Kidney Int. 100, 753&#x2013;779 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34556300</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2021.05.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64, 797&#x2013;808 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau, F. A. et al. The 10-year follow-up data of the Euro-Lupus Nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61&#x2013;64 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19155235</ArticleId><ArticleId IdType="doi">10.1136/ard.2008.102533</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi, M. et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 89, 235&#x2013;242 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26489028</ArticleId><ArticleId IdType="doi">10.1038/ki.2015.318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu, C.-Y. et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology 56, 620&#x2013;628 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28039419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C., Lau, C. S. &amp; Wong, R. W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831&#x2013;837 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9588734</ArticleId><ArticleId IdType="doi">10.1002/1529-0131(199805)41:5&lt;831::AID-ART9&gt;3.0.CO;2-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. Mycophenolate mofetil for lupus nephritis: an update. Expert. Rev. Clin. Immunol. 11, 1353&#x2013;1364 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26364748</ArticleId><ArticleId IdType="doi">10.1586/1744666X.2015.1087314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann. Rheum. Dis. 79, 1070&#x2013;1076 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32448782</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-217178</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18&#x2013;26 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25383558</ArticleId><ArticleId IdType="doi">10.7326/M14-1030</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 75, 30&#x2013;36 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25550339</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2014-206456</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin, H. A., Illei, G. G., Braun, M. J. &amp; Balow, J. E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20, 901&#x2013;911 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19297556</ArticleId><ArticleId IdType="pmc">2663831</ArticleId><ArticleId IdType="doi">10.1681/ASN.2008060665</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222&#x2013;233 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20039413</ArticleId><ArticleId IdType="pmc">4548300</ArticleId><ArticleId IdType="doi">10.1002/art.27233</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215&#x2013;1226 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22231479</ArticleId><ArticleId IdType="doi">10.1002/art.34359</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Lagares, C. et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun. Rev. 11, 357&#x2013;364 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22032879</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2011.10.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrier, B. et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. Arthritis Rheum. 62, 2458&#x2013;2466 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20506527</ArticleId><ArticleId IdType="doi">10.1002/art.27541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryd&#xe9;n-Aulin, M. et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci. Med. 3, e000163 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27651920</ArticleId><ArticleId IdType="pmc">5013507</ArticleId><ArticleId IdType="doi">10.1136/lupus-2016-000163</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721&#x2013;731 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918&#x2013;3930 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22127708</ArticleId><ArticleId IdType="pmc">5007058</ArticleId><ArticleId IdType="doi">10.1002/art.30613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl, W. et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 69, 1016&#x2013;1027 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28118533</ArticleId><ArticleId IdType="pmc">5434872</ArticleId><ArticleId IdType="doi">10.1002/art.40049</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, F. et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann. Rheum. Dis. 77, 355&#x2013;363 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29295825</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-211631</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner, H. I. et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann. Rheum. Dis. 79, 1340&#x2013;1348 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32699034</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-217101</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria, A. et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 70, 1256&#x2013;1264 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29671280</ArticleId><ArticleId IdType="pmc">6099508</ArticleId><ArticleId IdType="doi">10.1002/art.40511</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslen, T. et al. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Sci. Med. 8, e000459 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33568389</ArticleId><ArticleId IdType="pmc">7878136</ArticleId><ArticleId IdType="doi">10.1136/lupus-2020-000459</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesar, V. &amp; Hruskova, Z. Belimumab in the management of systemic lupus erythematosus &#x2014; an update. Expert. Opin. Biol. Ther. 17, 901&#x2013;908 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28460578</ArticleId><ArticleId IdType="doi">10.1080/14712598.2017.1324846</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino, L. et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J. Autoimmun. 86, 1&#x2013;8 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28935492</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2017.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis, A. et al. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study. Semin. Arthritis Rheum. 48, 467&#x2013;474 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29555348</ArticleId><ArticleId IdType="doi">10.1016/j.semarthrit.2018.02.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736&#x2013;745 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30926722</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil, M. F. et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci. Med. 8, e000590 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34930819</ArticleId><ArticleId IdType="pmc">8689160</ArticleId><ArticleId IdType="doi">10.1136/lupus-2021-000590</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurkovich, M., Vostretsova, K., Chen, W. &amp; Avi&#xf1;a-Zubieta, J. A. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res. 66, 608&#x2013;616 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C., Ho, L. Y., Chan, K. L., Tse, S. M. &amp; To, C. H. Trend of survival of a cohort of Chinese patients with systemic lupus erythematosus over 25 years. Front. Med. 7, 552 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00552</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven, R. F. et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci. Med. 8, e000538 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34819388</ArticleId><ArticleId IdType="pmc">8614136</ArticleId><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 95, 219&#x2013;231 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30420324</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2018.08.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070&#x2013;2080 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33971155</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100&#x2013;107 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34615636</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int. J. Rheum. Dis. 16, 625&#x2013;636 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24382275</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.12212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap, D. Y. H., Ma, M. K. M., Mok, M. M. Y., Tang, C. S. O. &amp; Chan, T. M. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology 52, 480&#x2013;486 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23148090</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kes293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse, S. M. &amp; Mok, C. C. Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus. Lupus 26, 715&#x2013;722 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27831540</ArticleId><ArticleId IdType="doi">10.1177/0961203316676384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunyakham, W., Foocharoen, C., Mahakkanukrauh, A., Suwannaroj, S. &amp; Nanagara, R. Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Pac. J. Allergy Immunol. 30, 152&#x2013;157 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22830295</ArticleId></ArticleIdList></Reference><Reference><Citation>Condon, M. B. et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72, 1280&#x2013;1286 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23740227</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2012-202844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian, A. et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann. Rheum. Dis. 79, 339&#x2013;346 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31852672</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2019-216303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasitanon, N., Fine, D. M., Haas, M., Magder, L. S. &amp; Petri, M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15, 366&#x2013;370 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16830883</ArticleId><ArticleId IdType="doi">10.1191/0961203306lu2313oa</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel, G. J. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 61, 830&#x2013;839 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19479701</ArticleId><ArticleId IdType="pmc">2898742</ArticleId><ArticleId IdType="doi">10.1002/art.24538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dima, A., Jurcut, C., Chasset, F., Felten, R. &amp; Arnaud, L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther. Adv. Musculoskelet. Dis. 14, 1759720&#xd7;211073001 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">8848057</ArticleId><ArticleId IdType="doi">10.1177/1759720X211073001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenfant, T. et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology 59, 3807&#x2013;3816 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32442312</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaa157</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles, R. B. &amp; Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453&#x2013;1460 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25275721</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886&#x2013;1895 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22087680</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1014460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou, F. et al. Long-term follow-up of the MAINTAIN Nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann. Rheum. Dis. 75, 526&#x2013;531 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25757867</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2014-206897</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni, G. et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol. 1, 925&#x2013;932 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17699309</ArticleId><ArticleId IdType="doi">10.2215/CJN.02271205</ArticleId></ArticleIdList></Reference><Reference><Citation>Argolini, L. M. et al. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. J. Nephrol. 34, 389&#x2013;398 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32462476</ArticleId><ArticleId IdType="doi">10.1007/s40620-020-00753-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi, T., Wakasugi, N., Uno, S. &amp; Makino, H. Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5-year interim postmarketing surveillance study in Japan (TRUST). J. Rheumatol. 48, 74&#x2013;81 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32238515</ArticleId><ArticleId IdType="doi">10.3899/jrheum.191008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, Q. et al. Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. Ann. Rheum. Dis. https://doi.org/10.1136/ard-2022-222486 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222486</ArticleId><ArticleId IdType="pubmed">36442978</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourde-Chiche, N. et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann. Rheum. Dis. 81, 1420&#x2013;1427 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35725295</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2022-222435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G. et al. Association of urinary matrix metalloproteinase 7 levels with incident renal flare in lupus nephritis. Arthritis Rheumatol. 73, 265&#x2013;275 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32892475</ArticleId><ArticleId IdType="doi">10.1002/art.41506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet, J. M. et al. Association between urinary epidermal growth factor and renal prognosis in lupus nephritis. Arthritis Rheumatol. 73, 244&#x2013;254 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32892508</ArticleId><ArticleId IdType="doi">10.1002/art.41507</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet, J. M., Malvar, A., Arazi, A. &amp; Rovin, B. H. The lupus nephritis management renaissance. Kidney Int. 101, 242&#x2013;255 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34619230</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2021.09.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. &amp; Mohan, C. Urinary biomarkers in lupus nephritis: are we there yet? Arthritis Rheumatol. 73, 194&#x2013;196 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32892509</ArticleId><ArticleId IdType="doi">10.1002/art.41508</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou, F. et al. A proteinuria cut-off level of 0.7&#x2009;g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial. Lupus Sci. Med. 2, e000123 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26629352</ArticleId><ArticleId IdType="pmc">4654096</ArticleId><ArticleId IdType="doi">10.1136/lupus-2015-000123</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era, M. et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-lupus nephritis cohort. Arthritis Rheumatol. 67, 1305&#x2013;1313 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25605554</ArticleId><ArticleId IdType="doi">10.1002/art.39026</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar, A. et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol. Dial. Transpl. 32, 1338&#x2013;1344 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfv296</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado, A. S. et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 23, 840&#x2013;847 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24401872</ArticleId><ArticleId IdType="doi">10.1177/0961203313518625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakasugi, D. et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J. Rheumatol. 39, 79&#x2013;85 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22089455</ArticleId><ArticleId IdType="doi">10.3899/jrheum.110532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabaleta-Lanz, M. E. et al. Further description of early clinically silent lupus nephritis. Lupus 15, 845&#x2013;851 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17211989</ArticleId><ArticleId IdType="doi">10.1177/0961203306070002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chedid, A. et al. Low-level proteinuria in systemic lupus erythematosus. Kidney Int. Rep. 5, 2333&#x2013;2340 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33305127</ArticleId><ArticleId IdType="pmc">7710831</ArticleId><ArticleId IdType="doi">10.1016/j.ekir.2020.09.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zickert, A., Sundelin, B., Svenungsson, E. &amp; Gunnarsson, I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci. Med. 1, e000018 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25379188</ArticleId><ArticleId IdType="pmc">4213828</ArticleId><ArticleId IdType="doi">10.1136/lupus-2014-000018</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis, I. et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology 59, 3424&#x2013;3434 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32353879</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaa129</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis, I., Tamirou, F. &amp; Houssiau, F. A. Treat-to-target in lupus nephritis. what is the role of the repeat kidney biopsy? Arch. Immunol. Ther. Exp. 70, 8 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-022-00646-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar, A. et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int. 97, 156&#x2013;162 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31685314</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2019.07.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H. et al. Multitarget therapy for maintenance treatment of lupus nephritis. J. Am. Soc. Nephrol. 28, 3671&#x2013;3678 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28760751</ArticleId><ArticleId IdType="pmc">5698076</ArticleId><ArticleId IdType="doi">10.1681/ASN.2017030263</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena, A., Teng, Y. K. O., Collins, C., England, N. &amp; Leher, H. Voclosporin lupus nephritis: results two-year AURORA 2 continuation study. Ann. Rheum. Dis. 81, 325 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.4162</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383, 1117&#x2013;1128 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32937045</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 101, 403&#x2013;413 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34560137</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2021.08.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki, Y. et al. Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. Rheumatology 61, 3614&#x2013;3636 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34962998</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keab953</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz, M. B. et al. Impact of belimumab on organ damage in systemic lupus erythematosus. Arthritis Care Res. 74, 1822&#x2013;1828 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24901</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven, R. F. et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a phase III study extension. Rheumatology 59, 281&#x2013;291 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31302695</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kez279</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven, R. et al. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci. Med. 9, e000634 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35346982</ArticleId><ArticleId IdType="pmc">8961173</ArticleId><ArticleId IdType="doi">10.1136/lupus-2021-000634</ArticleId></ArticleIdList></Reference><Reference><Citation>Md Yusof, M. Y. et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann. Rheum. Dis. 76, 1829&#x2013;1836 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28684557</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-211191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus, M. N., Turner-Stokes, T., Chavele, K.-M., Isenberg, D. A. &amp; Ehrenstein, M. R. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology 51, 1208&#x2013;1215 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22337941</ArticleId><ArticleId IdType="pmc">3380246</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/ker526</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy, V. et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology 56, 1227&#x2013;1237 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28407142</ArticleId><ArticleId IdType="pmc">5808665</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kex067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysler, E. F. et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 65, 2368&#x2013;2379 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23740801</ArticleId><ArticleId IdType="doi">10.1002/art.38037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenstein, M. R. &amp; Wing, C. The BAFFling effects of rituximab in lupus: danger ahead? Nat. Rev. Rheumatol. 12, 367&#x2013;372 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26888554</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2016.18</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij, T. et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol. Dial. Transpl. 36, 1474&#x2013;1483 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfaa117</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha-Fregoso, Y. et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 73, 121&#x2013;131 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32755035</ArticleId><ArticleId IdType="doi">10.1002/art.41466</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipa, M. et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial. Ann. Intern. Med. 174, 1647&#x2013;1657 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34698499</ArticleId><ArticleId IdType="doi">10.7326/M21-2078</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng, Y. K. O. et al. Pharmacodynamic effect of sequential belimumab and rituximab therapy in patients with systemic lupus erythematosus: the phase 3, randomized, placebo-controlled BLISS-BELIEVE study [Abstract]. Ann. Rheum. Dis. 81, 186 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.2433</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211&#x2013;221 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne, D. et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 81, 496&#x2013;506 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35144924</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, e208&#x2013;e219 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, Q. Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date. BioDrugs 34, 111&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31916225</ArticleId><ArticleId IdType="doi">10.1007/s40259-019-00400-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuqayyas, L. et al. Safety and biological activity of rozibafusp alfa, a bispecific inhibitor of inducible costimulator ligand and B cell activating factor, in patients with rheumatoid arthritis: results of a phase 1b, randomized, double-blind, placebo-controlled, multiple ascending dose study. ACR Open Rheumatol. 4, 903&#x2013;911 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35899378</ArticleId><ArticleId IdType="pmc">9555197</ArticleId><ArticleId IdType="doi">10.1002/acr2.11487</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner, T. et al. Treatment of primary Sj&#xf6;gren&#x2019;s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann. Rheum. Dis. 78, 641&#x2013;647 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30826774</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-214720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman, S. J. et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj&#xf6;gren&#x2019;s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399, 161&#x2013;171 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34861168</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)02251-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. Expert. Rev. Clin. Immunol. 13, 677&#x2013;692 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28443384</ArticleId><ArticleId IdType="doi">10.1080/1744666X.2017.1323635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, M.-T., Chao, C.-T. &amp; Lin, S.-H. Chronic kidney disease: strategies to retard progression. Int. J. Mol. Sci. 22, 10084 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34576247</ArticleId><ArticleId IdType="pmc">8470895</ArticleId><ArticleId IdType="doi">10.3390/ijms221810084</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse, K. C. et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14, 947&#x2013;952 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16425574</ArticleId><ArticleId IdType="doi">10.1191/0961203305lu2249oa</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, J. C., Weiss, P. F., Xiao, R., Atkinson, M. A. &amp; Wenderfer, S. E. Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation. Kidney Int. 102, 395&#x2013;404 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35618096</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2022.04.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Vecchio, L., Beretta, A., Jovane, C., Peiti, S. &amp; Genovesi, S. A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease. Drugs 81, 1491&#x2013;1511 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34363606</ArticleId><ArticleId IdType="doi">10.1007/s40265-021-01573-3</ArticleId></ArticleIdList></Reference><Reference><Citation>De Nicola, L. et al. Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease? J. Nephrol. 35, 1605&#x2013;1618 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35583597</ArticleId><ArticleId IdType="pmc">9300572</ArticleId><ArticleId IdType="doi">10.1007/s40620-022-01336-7</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe4;emann, M. &amp; Kronbichler, A. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. Ann. Rheum. Dis. 81, 614&#x2013;617 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34844933</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221474</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103&#x2013;1112 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19369404</ArticleId><ArticleId IdType="pmc">2678035</ArticleId><ArticleId IdType="doi">10.1681/ASN.2008101028</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg, D. et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49, 128&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19933596</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kep346</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler, E. et al. Phase III/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol. 74, 112&#x2013;123 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34164944</ArticleId><ArticleId IdType="doi">10.1002/art.41900</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda, H., Fukusumi, Y., Ivanov, V., Zhang, Y. &amp; Kawachi, H. Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton. FASEB J. 35, e21983 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34662453</ArticleId><ArticleId IdType="doi">10.1096/fj.202101052R</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital, E. M. et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann. Rheum. Dis. 81, 951&#x2013;961 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35338035</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooles, F. A. H. &amp; Isaacs, J. D. The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. Lancet Rheumatol. 4, e61&#x2013;e72 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00254-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce, I. N. et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatol. 3, e101&#x2013;e110 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30342-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolin, K. et al. Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One 8, e84450 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24386384</ArticleId><ArticleId IdType="pmc">3873995</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0084450</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, K. E. et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 4, e1000084 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18516230</ArticleId><ArticleId IdType="pmc">2377340</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1000084</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid, S. et al. Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 80, 1183&#x2013;1189 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33766895</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-219727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg, N. et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-&#x3b3; production in T cells from patients with SLE. Ann. Rheum. Dis. 77, 1070&#x2013;1077 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29475858</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-212794</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasni, S. A. et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat. Commun. 12, 3391 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34099646</ArticleId><ArticleId IdType="pmc">8185103</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-23361-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Anolik, J. H. et al. The relationship of FcR&#x3b3;IIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455&#x2013;459 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12571855</ArticleId><ArticleId IdType="doi">10.1002/art.10764</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, J. I. et al. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. EBioMedicine 86, 104343 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36371989</ArticleId><ArticleId IdType="pmc">9663864</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahadat, M. J. et al. Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicenter longitudinal study. Rheumatology 61, 4344&#x2013;4354 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35143620</ArticleId><ArticleId IdType="pmc">9629374</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keac083</ArticleId></ArticleIdList></Reference><Reference><Citation>Garantziotis, P. et al. Molecular taxonomy of systemic lupus erythematosus through data-driven patient stratification: molecular endotypes and cluster-tailored drugs. Front. Immunol. 13, 860726 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35615355</ArticleId><ArticleId IdType="pmc">9125979</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.860726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y.-F. et al. Identification of shared and Asian-specific loci for systemic lupus erythematosus and evidence for roles of type III interferon signaling and lysosomal function in the disease: a multi-ancestral genome-wide association study. Arthritis Rheumatol. 74, 840&#x2013;848 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34783190</ArticleId><ArticleId IdType="doi">10.1002/art.42021</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen, K. A. et al. Analysis of trans-ancestral SLE risk loci identifies unique biologic networks and drug targets in African and European ancestries. Am. J. Hum. Genet. 107, 864&#x2013;881 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33031749</ArticleId><ArticleId IdType="pmc">7675009</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2020.09.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava, A. et al. Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis. Arthritis Rheumatol. 74, 829&#x2013;839 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34783463</ArticleId><ArticleId IdType="doi">10.1002/art.42023</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, T., Duran, V., Vanarsa, K. &amp; Mohan, C. Targeted urine proteomics in lupus nephritis &#x2014; a meta-analysis. Expert. Rev. Proteom. 17, 767&#x2013;776 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2020.1874356</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh, S. V. et al. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int. 102, 845&#x2013;865 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35788359</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2022.05.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Der, E. et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat. Immunol. 20, 915&#x2013;927 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31110316</ArticleId><ArticleId IdType="pmc">6584054</ArticleId><ArticleId IdType="doi">10.1038/s41590-019-0386-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaani, S. et al. Rethinking lupus nephritis classification on a molecular level. J. Clin. Med. 8, E1524 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8101524</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>